Patients’ characteristics (n=102)
| Characteristic | N (%) | Characteristic | N (%) |
| Gender | T stage* | ||
| Female | 18 (17.6) | 1 | 40 (39.2) |
| Male | 84 (82.4) | 2 | 47 (46.1) |
| Age, median, years | 62 | 3 | 13 (12.7) |
| <70 | 79 (77.5) | 4 | 2 (2.0) |
| ≥70 | 23 (22.5) | N stage* | |
| Smoking status | 0 | 44 (43.2) | |
| Non-smoker | 58 (56.9) | 1 | 23 (22.5) |
| Smoker | 44 (43.1) | 2 | 34 (33.3) |
| SCLC staging* | 3 | 1 (1) | |
| I–II | 60 (58.8) | Metastasis† | |
| III | 42 (41.2) | No | 98 (96.1) |
| Postoperative treatment‡ | Yes | 4 (3.9) | |
| Not receive | 35 (34.3) | ||
| Chemotherapy | 40 (39.2) | ||
| Radiotherapy | 1 (0.01) | ||
| Chemotherapy plus radiotherapy | 26 (25.5) | ||
The cohort was also used to explore FOXP3 and HLA class II expression in SCLC.
*Pathological stage.
†Clinical stage: metastasis considered by clinical imaging before surgery.
‡All treatment after surgery.
N, lymph node; SCLC, small cell lung cancer; T, tumor.